This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action

BERKELEY, Calif., May 6, 2014 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors of the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) ("CytRx" or "the Company") and the May 13, 2014 deadline to file for lead plaintiff. Investors who have suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing CytRx@hbsslaw.com, calling 510-725-3000 or visiting http://hb-securities.com/investigations/CytRx.

The securities fraud class-action lawsuit filed against CytRx on March 14, 2014 is on behalf of all persons who purchased or otherwise acquired CytRx stock between Nov. 20, 2013 and March 13, 2014 (the "Class Period"). The lawsuit also covers those who purchased CytRx stock in the offering completed February 5, 2014, in which CytRx netted more than $80 million.

The complaint, filed in the U.S. District Court for the Central District of California, alleges that the defendant violated federal securities laws when it employed The DreamTeam Group to write misleading articles under aliases without disclosing payment for the articles or any affiliation with the company. The complaint alleges that following the dissemination of CytRx's alleged false stock-promoting statements, the company's stock reached a high of $8.35 per share on Jan. 30, 2014.

On Feb. 5 2014, CytRx completed the sale of more than 11 million shares at $6.50 per share, acquiring more than $80 million in net proceeds, according to the complaint.

On Feb. 12, 2014, a senior columnist at TheStreet.com published an article, titled "Galena Biopharma Pays For Stock-Touting Campaign While Insiders Cash Out Millions," claiming an affiliated biotechnology company was engaging in a misleading campaign to boost the company's stock price. Following its publication, CytRx's alleged stock-touting practices and employment of the same firm – DreamTeam – were unveiled. Following this news, CytRx's stock price fell from $6.60 to a close of $6.04, declining in value 8.5 percent and damaging investors, according to the complaint.

On March 13, 2014, an additional published report alleged that CytRx shares quadrupled during a promotion via DreamTeam and that company management edited and approved the paid articles, according to the complaint. Following publication of the article, CytRx stock fell from $4.78 per share to a close of $4.17 per share on March 13, 2014. CytRx's stock continues to trade below previous figures, closing at $3.37 on May 5, 2014.

"CytRx's stock took a nosedive following this news, which leads us to believe that claims being made about the company's dealings were not entirely forthright," said Mr. Kathrein. " Hagens Berman intends to act for the best interest of shareholders to uncover the story here and is continuing its determined investigation into CytRx's actions."

The deadline to file for lead plaintiff in the securities fraud class action is May 13, 2014.

Persons with non-public information regarding CytRx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information call Reed Kathrein at 510-725-3000 or email one of the links above.

About Hagens BermanHagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in nine cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hb-securities.com. Read the firm's Securities Newsletter at http://www.hb-securities.com/newsletter.

ContactsFirmani + Associates Mark Firmani, 206-443-9357 mark@firmani.com

SOURCE Hagens Berman Sobol Shapiro LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs